News from Freeline
Charlotte2021-12-13T18:27:08+01:00Freeline announced new data from its ongoing Phase 1/2 MARVEL-1 dose-finding clinical trial of FLT190 for the treatment of Fabry disease and provided updates on its pipeline programs.
News from Idorsia
Charlotte2021-12-13T18:15:52+01:00Idorsia Ltd (SIX: IDIA) today announced that after the planned interim analysis of the open-label extension (OLE) of the Phase 3 MODIFY study with lucerastat for the treatment of adult patients with Fabry disease, the study will continue.
The African Summit on Rare Diseases
Charlotte2022-02-08T16:37:17+01:00The African Summit on Rare Diseases 2021
Focus on Fabry Leaders around the world
Charlotte2021-12-20T14:03:51+01:00Interview with Yifan Xu from Fabry China When did you join your national patient association? I joined Fabry China in 2016. At that time the community was only founded since a few months. There were only 10 members. You could hardly say it was an organization, actually more like just a [...]
News from Sangamo Therapeutics
Charlotte2021-11-04T17:15:33+01:00Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
News from Takeda: Update to FOS Registry
Charlotte2021-11-03T16:00:34+01:00News from Takeda: Update to FOS Registry
Webinar: Fabry & the Brain
Charlotte2022-02-08T16:37:59+01:00Fabry Findings Webinar: Fabry & the Brain now available on our YouTube Channel
Fabry Outcome Survey- Annual Report 2020
Charlotte2022-02-08T16:37:44+01:00Throughout 2020, the COVID-19 pandemic posed many challenges for both FOS and the wider Fabry disease community. The members of the FOS Steering Committee and I would like to thank all patients and caregivers involved in the registry for their extremely valuable contributions and for their continued commitment to [...]